Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
31 mai 2022 08h00 HE
|
Timber Pharmaceuticals
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber"...